Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Overview

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Companies Involved in Therapeutics Development

Atlantic Healthcare Plc

China Medical System Holdings Ltd

Phio Pharmaceuticals Corp

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Drug Profiles

alicaforsen sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit ICAM-1 for Oncology and Retinal Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMS-024 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNP-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melittin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MS-553 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Dormant Products

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Discontinued Products

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Product Development Milestones

Featured News & Press Releases

Nov 12, 2018: Atlantic Healthcare to present a poster at the Crohns & Colitis Foundation IBD: Innovate conference in New York on Tuesday, November 13, 2018

Nov 12, 2018: Atlantic Healthcare to present at the Stifel 2018 Healthcare Conference in New York

Sep 27, 2018: Atlantic Healthcare reports results from Phase 1 trial of tablet for Crohn’s

Sep 13, 2018: Atlantic Healthcare secures acceptance of brand name Camligo for alicaforsen enema to treat pouchitis

Aug 02, 2018: Strategic appointment expands Atlantic Healthcare executive team

May 02, 2018: Atlantic Healthcare completes patient enrollment to its Phase 3 study of alicaforsen to treat IBD Pouchitis

Jan 08, 2018: Atlantic Healthcare is attending the JP Morgan Healthcare Conference and the Crohn's and Colitis Congress

Nov 08, 2017: Atlantic Healthcare to present at the Stifel 2017 Healthcare Conference in New York on November 15, 2017

May 30, 2017: Atlantic Healthcare develops tablet formulations of alicaforsen to treat Crohn's disease and Ulcerative Colitis

May 22, 2017: Atlantic Healthcare announces strengthening of the Board as it prepares for commercialisation of alicaforsen in its first indication

May 01, 2017: Atlantic Healthcare initiates FDA rolling submission of its New Drug Application for alicaforsen in the treatment of pouchitis

Apr 24, 2017: Atlantic Healthcare appoints Durbin as Nordic regions distributor of alicaforsen under the Named Patient Programme

Mar 22, 2017: Atlantic Healthcare announces Chairman to step down as company enters next phase of preparing for product commercialisation

Feb 28, 2017: Atlantic Healthcare confirms alicaforsen targets TLR-9, providing a second mechanism of action to treat new and existing inflammatory indications

Jan 24, 2017: Atlantic Healthcare receives FDA agreement to initiate rolling submission of its New Drug Application for alicaforsen in the treatment of pouchitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H1 2019

Summary

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Intercellular Adhesion Molecule 1 (ICAM-1) is a protein encoded by the ICAM1 gene. It acts as a receptor for major receptor group rhinovirus A-B capsid proteins and Coxsackievirus A21 capsid proteins. ICAM1 promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation.

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Immunology, Central Nervous System, Genito Urinary System And Sex Hormones and Ophthalmology which include indications Cholangitis, Crohn's Disease (Regional Enteritis), Hepatocellular Carcinoma, Inflammation, Kidney Fibrosis, Liver Fibrosis, Multiple Sclerosis, Pancreatic Islet Transplant Rejection, Pouchitis, Refractory Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis and Ulcerative Colitis.

The latest report Intercellular Adhesion Molecule 1 - Pipeline Review, H1 2019, outlays comprehensive information on the Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1)
- The report reviews Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope